shown to affect approximately one-third of PWH as measured by EQ-5D-3L, 6 and in another study, 37% of PWH met the criteria for depression as measured by the Patient Health Questionnaire (PHQ-9), a scale used to grade the severity of depressive symptoms in adults. 7 However, like other aspects of HRQoL, the impact of hemophilia on emotional well-being remains infrequently addressed in the clinical setting. Neither generic nor disease-specific patient-reported outcome (PRO) instruments are consistently used in the comprehensive care setting or to individualize hemophilia treatment. Greater experience with and validation of PRO instruments in PWH may increase the use of these instruments for clinical outcome monitoring and may offer opportunities to improve patient dialog and management of specific outcomes.
The Pain, Functional Impairment, and Quality of Life (P-FiQ) study was developed to evaluate pain and HRQoL in men with hemophilia and a history of joint pain or bleeding, and to demonstrate the reliability and validity of 5 generic and disease-specific PRO instruments in PWH. Each of these instruments differs in recall periods (ie, ranging from "today" to over the past month) and levels of detail (ie, numbers of items related to each outcome) and therefore provides distinct information regarding specific patient outcomes. High reliability and validity of these instruments in the P-FiQ population were observed and have been reported, [8] [9] [10] [11] supporting the use of these tools in accurately measuring pain and HRQoL. Additionally, overall PRO instrument domain scores within P-FiQ have been reported, demonstrating the broad impact of hemophilia on pain and other aspects of HRQoL. 10 The analysis presented here explores the results of these PRO instruments in more detail, focusing on individual item responses and specific assessments of each outcome, which may offer greater insight into the effects of hemophilia on HRQoL.
| METHODS

| Participants
The P-FiQ study was a non-interventional, cross-sectional study of adult males with mild to severe hemophilia A or B (with or without inhibitors) and a history of joint pain or bleeding. Fifteen US sites enrolled participants during routine comprehensive care visits between October 2013 and October 2014. Individuals who were not able to provide consent, could not complete the survey in English, or had already participated in the study were not eligible for enrollment.
| Pain history, functional status, and PRO instruments
Participants completed a survey that included demographic information, hemophilia-related health history, current treatment regimen for bleeding, pain description, pain management strategies, and functional
status (Centers for Disease Control and Prevention-Universal Data
Collection [CDC-UDC]). In addition, site personnel completed a survey including information on participants' medical history and CDC-UDC functional status and joint range of motion questions. 5 Participants also completed 5 PRO instruments, including the EQ-5D-5L with visual analog scale (VAS), Brief Pain Inventory v2 Short Form (BPI),
International Physical Activity Questionnaire (IPAQ), SF-36v2, and
Hemophilia Activities List (HAL). Pain, functional impairment, anxiety, and depression were assessed in detail via the EQ-5D-5L, BPI, SF36v2, and HAL.
The EQ-5D-5L PRO scale evaluated mobility, self-care, usual activities, pain and discomfort, and anxiety and depression in patients "today" using 5 levels of descriptive measurements: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ-5D VAS was used to evaluate health "today."
Participants were asked to indicate how good or bad their health was that day by marking an "X" on a 20-cm scale ranging from 0 (worst health imaginable) to 100 (best health imaginable).
Pain severity and pain interference over the last 7 days were measured using the BPI. For pain severity, patients rated their current, The overall sum score was measured on a scale of 0 (worst function)
to 100 (best function).
| Statistical analysis
All data were summarized for analysis using descriptive statistics.
Standard scoring procedures were used to calculate total scores and domain/composite scores for the SF-36v2 and HAL. Pain severity and pain interference as measured by the BPI were calculated as the mean of the responses to the items in each of these 2 domains.
| RESULTS
| Participant characteristics
Overall, 381 adult males (aged ≥18 years) with hemophilia were enrolled in P-FiQ. The median age (Q1, Q3) of participants was 34 (26.3, 47.2) years. The majority of those enrolled had hemophilia A (77%); 23% had hemophilia B and 9% had inhibitors. A large percentage were overweight or obese (65%), and similarly, 65% had self-reported arthritis/bone/joint problems. Half (50%) of participants reported a history of joint procedures or surgeries. Patient-and site-reported rates of functional disability in the past 6 months (CDC-UDC scale 5 ) were 66% and 59%, respectively.
Participants had some college or above education (61%) and were employed (77%) and 65% were married or had a long-term partner.
Fifty-one percent of participants had hepatitis C virus, and 16% had human immunodeficiency virus. Patient-and site-reported rates of depression were 16% and 19%, respectively; of those with site-reported depression, 36% were receiving antidepressants. Patient-and sitereported rates of anxiety were each 14%; of those with site-reported anxiety, 26% were receiving anxiolytics. Median (Q1, Q3) EQ-5D VAS score (range, 0-100), reflecting "your health today," was 80 (66, 90).
Index score (range, −0.11-1), derived from the EQ-5D-5L item responses, was 0.796 (0.678, 0.861).
| Pain
Pain was assessed by 1 item on the EQ-5D-5L (measured "today") and 2 items on the SF-36v2 (measured over the past 4 weeks). Most participants (76%) reported pain/discomfort "today" on EQ-5D-5L, with 14% reporting severe or extreme pain/discomfort ( Figure 1A ). Median (Q1, Q3) SF-36v2 bodily pain domain score (range, 0-100), reflecting pain and pain interference over the past 4 weeks, was 41.8 (37.2, 51.1).
During the past 4 weeks, 90% of participants reported bodily pain (44% moderate or severe), and 75% reported pain that interfered with normal work/housework (24% quite a bit or extremely; Figure 1B ).
The BPI survey evaluated pain severity including pain levels in each joint and the extent to which pain interfered with activities and quality of life in the past 7 days using 21 response items. Median (Q1, Q3) BPI pain severity composite score (range, 0-10), reflecting pain "in the last week," was 3.3 (1.3, 5.0). Specifically, worst, least, average, and current pain severity item scores are shown in Figure 1C . Ankles and knees were associated with the most severe pain. Median (Q1, Q3) BPI pain interference composite score (range, 0-10) was 2.7 (0.6, 5.4). Specifically, respondents reported that pain most affected general activity (74%), mood (73%), walking ability (70%), and normal work (71%), and least affected relations with other people (56%; Figure 1D ).
| Functional impairment
Functional impairment was assessed by 3 items on the EQ-5D-5L.
Participants reported problems "today" with mobility (61%), usual activities (53%), and self-care (19%; Figure 2A ). The SF-36v2 ques- flights of stairs (59%; Figure 2B ). Physical problems caused participants to limit kinds of work/activities (69%), accomplish less than they would like (66%), have difficulty in performing work/activities (65%), and cut down time spent on work/activities (62%; Figure 2C ).
The Hemophilia Activities List assessed functional impairment over the past month. The Hemophilia Activities List domain/composite scores related to functional impairment are presented in Table 1 . In general, greater difficulties were seen for lower compared with upper extremity functions and activities. Within the lying down/sitting/ kneeling/standing domain, the most frequent problems in the previous month were squatting for a long time (74%), kneeling for a long time (73%), standing for a long time (72%), and kneeling/squatting (70%).
Within the leisure activities and sports domain, the most frequent problems in the previous month were sports (61%) and playing games
outdoors (56%). Within the functions of the legs and arms domains, the most frequent problems in the previous month were jumping (71%), running (71%), lifting heavy objects (70%), and carrying heavy objects (69%; Figure 2D ).
| Anxiety and depression
Anxiety and depression were assessed by 1 item on the EQ-5D-5L
and several items on the SF-36v2. Anxiety/depression "today" on EQ-5D-5L was reported by 43% (severe or extreme 6%) as shown in Figure 3A . On SF-36v2, median (Q1, Q3) domain scores related to mental health over the past 4 weeks (range, 0-100) were as follows: vitality, Figure 3B ).
During the past 4 weeks, participants reported feeling tired (93%), worn out (86%), very nervous (68%), downhearted and depressed (55%), and so down in the dumps that nothing could cheer them up (41%; Figure 3C ); however, within the same time frame, they also reported feeling happy (98%), calm and peaceful (95%), full of life (96%), and full of energy (90%; Figure 3D ). During the past 4 weeks, 60% experienced physical/emotional problems that interfered with normal social activities (12% most or all of the time and 17% quite a bit or extremely).
| DISCUSSION
This analysis incorporates multiple PRO instruments to evaluate the prevalence and characteristics of pain, functional impairment, and anxiety and depression in 381 adult males with hemophilia enrolled in the P-FiQ study. Assessment of the reliability and validity of PRO instruments in previous P-FiQ publications demonstrates the accuracy of these tools in measuring pain and HRQoL in this study population. [8] [9] [10] [11] Here, we report trends across the PRO instruments specific to patient-reported pain, functional impairment, and anxiety and depression among P-FiQ respondents. Together these data support the conclusion that these important concepts can be measured in PWH with any of the instruments used in the P-FiQ study. Overall, these data indicate that pain and HRQoL outcomes can be measured across various PRO instruments. Although the HAL is a disease-specific instrument and was designed to assess functional limitations associated with hemophilia, other PRO instruments used in P-FiQ were developed and validated in other disease states, and extensive literature has been generated documenting their use in cancer-related, musculoskeletal, and other types of non-cancer pain. [14] [15] [16] [17] [18] [19] [20] [21] A potential limitation of this study was selection bias, as participants were only included if they had a history of joint pain or bleeding. Therefore, our findings may be reflective of the most symptomatic individuals, and the prevalence of pain and HRQoL issues cannot be assumed to apply to the overall hemophilia population.
HRQoL outcomes may also be expected to vary with measurable patient characteristics, such as education, employment status, and types of pain. These correlations are explored further and the contribution of patient characteristics to pain and functional outcomes is formally modeled as additional analyses of P-FiQ data presented in this supplement. Together, these analyses offer a detailed assessment of HRQoL outcomes among PWH with a history of joint pain or bleeding, and provide insight into how patient characteristics influence the perception of physical function and emotional well-being.
| CONCLUSIONS
Pain and HRQoL were measured in PWH using multiple existing PRO instruments. The choice of instrument depends on the purpose(s) for which the data are being collected, as each instrument has varying characteristics that affect the interpretability and utility of its results. Given the prevalence of pain, functional impairment due to joint disease, and mental health problems in individuals with hemophilia, strong consideration should be given to including measures of these outcomes in clinical practice and clinical research studies. Kempton has served as a consultant for Baxalta, Genentech, and Novo
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